GlassScriptPhysician profile
Bryan Anthony Mcclelland
NPI 1790815934
$3,322.60
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $673 · 2020: $1,053 · 2021: $873 · 2022: $723.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $336.41 | 2020-2022 | |
| Glaxosmithkline, LLC. | $302.89 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $301.56 | 2019-2022 | |
| Allergan, INC. | $243.45 | 2019-2020 | |
| Amgen INC. | $237.92 | 2019-2021 | |
| Lilly USA, LLC | $236.66 | 2019-2022 | |
| Pfizer INC. | $194.59 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $190.55 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $165.11 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $143.63 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $67.59 | 2019-2020 | |
| Horizon Therapeutics Plc | $57.83 | 2020-2021 | |
| Astellas Pharma US INC | $56.64 | 2019-2020 | |
| Novo Nordisk INC | $55.46 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $53.78 | 2019-2020 |
Show all 40 companies
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Mcclelland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.